Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2 metastatic breast cancer with and without brain metastases (HER2CLIMB).

Giuseppe Curigliano; Volkmar Mueller; Virginia F Borges; Erika P Hamilton; Sara A Hurvitz; Sherene Loi; Rashmi Krishna Murthy; Alicia Frances Clare Okines; Elisavet Paplomata; David A Cameron; Lisa A Carey; Karen A Gelmon; Gabriel N Hortobagyi; Ian E Krop; Sibylle Loibl; Mark D Pegram; Dennis J Slamon; Jorge Ramos; Chiyu Zhang; Eric P Winer

Conference Proceedings

Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2 metastatic breast cancer with and without brain metastases (HER2CLIMB).

Giuseppe Curigliano, Volkmar Mueller, Virginia F Borges, Erika P Hamilton, Sara A Hurvitz, Sherene Loi, Rashmi Krishna Murthy, Alicia Frances Clare Okines, Elisavet Paplomata, David A Cameron, Lisa A Carey, Karen A Gelmon, Gabriel N Hortobagyi, Ian E Krop, Sibylle Loibl, Mark D Pegram, Dennis J Slamon, Jorge Ramos, Chiyu Zhang, Eric P Winer

JOURNAL OF CLINICAL ONCOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2021

DOI: 10.1200/JCO.2021.39.15_suppl.1043

Abstract

1043 Background: Tucatinib (TUC) is an oral tyrosine kinase inhibitor (TKI) highly specific for HER2. TUC is approved for use in combination with trastuzumab (T) and capecitabine (C) in patients (pts) with and without brain metastases (BM) who have received 1 or more prior anti-HER2–based regimens in the metastatic setting. In the primary analysis from the pivotal HER2CLIMB trial, the addition of TUC to T and C in pts with HER2+ metastatic breast cancer showed a statistically significant and clinically meaningful prolongation of progression-free (PFS) (HR = 0.54 [95% CI: 0.42, 0.71]; P < 0.001) and overall survival (OS) (HR = 0.66 [95% CI: 0.50, 0.88]; P = 0.005) (Murthy, et al. NEJM 2020)...

View full abstract